Abstract
Accumulating data from animal models of type 1 diabetes and some findings from clinical studies suggest that autoimmune destruction of islet beta cells is associated with enhanced beta cell regeneration. Successful immune therapies, aimed at preservation of islet cell mass, result in a remarkable reduction of beta cell regeneration. Treated or not, as long as the task of treatment is limited by "making peace" with autoimmunity, the process of beta cell loss continues. Additional therapeutic modalities capable of stimulating beta cell regeneration in the absence of active autoimmune destruction are urgently needed.
MeSH terms
-
Animals
-
Autoimmunity
-
Diabetes Mellitus, Experimental / immunology*
-
Diabetes Mellitus, Experimental / pathology
-
Diabetes Mellitus, Experimental / physiopathology
-
Diabetes Mellitus, Type 1 / immunology*
-
Diabetes Mellitus, Type 1 / pathology
-
Glucose Transporter Type 2 / analysis
-
Humans
-
Insulin / analysis
-
Insulin-Secreting Cells / immunology
-
Insulin-Secreting Cells / pathology*
-
Insulin-Secreting Cells / physiology
-
Islets of Langerhans / immunology
-
Islets of Langerhans / pathology
-
Islets of Langerhans / physiopathology
-
Male
-
Mice
-
Mice, Inbred NOD
-
Regeneration
Substances
-
Glucose Transporter Type 2
-
Insulin